Focus on Immunotherapy ALK Abelló specializes in allergy immunotherapy, presenting opportunities to offer complementary products, training, or partnerships in allergy treatment and prevention markets.
Recent Product Launches The launch of EURneffy in Germany and upcoming plans in the UK indicate active market expansion, creating chances to target healthcare providers and pharmacies involved in allergy management.
Strategic Alliances Partnerships with Meditab and investments in biotech firms like Allegriatx suggest an openness to technological innovation, opening avenues for digital health solutions or research collaborations.
Growth through Investment Recent funding activities, including the $5.1 million investment in Allegriatx, highlight potential for joint ventures, co-development projects, and tiered service offerings to support R&D efforts.
Limited Revenue, High Potential With revenues under $1 million, ALK Abelló presents opportunities for new product introductions or service enhancements aimed at expanding their market reach and increasing revenue streams in allergy care.
ALK Abelló uses 8 technology products and services including Veeam, SAP HANA, Microsoft Excel, and more. Explore ALK Abelló's tech stack below.
| ALK Abelló Email Formats | Percentage |
| First.Last@alk.net | 83% |
| FLast@alk.net | 9% |
| FirstLas@alk.net | 5% |
| First.Middle.Last@alk.net | 3% |
Civic and Social OrganizationsCommunity of Madrid, Spain11-50 Employees
ALK Abelló is a civic and social organization company based out of Calle Laguna del Marquesado Nª 19, Nave 16 Edificio Adriana 1ª Planta, Polígono Industrial La Resina (Villaverde), Madrid, Community of Madrid, Spain.
Company Overview
Media & News
Funding & FinancialsALK Abelló's revenue is estimated to be in the range of $1M
Funding & FinancialsALK Abelló's revenue is estimated to be in the range of $1M
1-888-653-2347 
support@leadiq.com